On the public citation graph
Is it time to nationalise the pharmaceutical industry?
0 signed · 34 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1016/s2213-8587(17)30041-4openalex-snapshot
Strategies to improve the affordability of insulin in the USA
inferredcites →https://doi.org/10.1080/00213624.1998.11506108openalex-snapshot
Economic Theories about the Benefits and Costs of Patents
inferredcites →https://doi.org/10.1080/08911916.2018.1549842openalex-snapshot
Financialized Corporations in a National Innovation System: The U.S. Pharmaceutical Industry
inferredcites →https://doi.org/10.1080/17487870.2018.1509712openalex-snapshot
Rethinking value in health innovation: from mystifications towards prescriptions
inferredcites →https://doi.org/10.1093/jlb/lsz019openalex-snapshot
From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine
inferredcites →https://doi.org/10.1186/s12916-016-0564-zopenalex-snapshot
Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom
inferredcites →https://doi.org/10.1371/journal.pmed.1001218openalex-snapshot
Innovation and Access to Medicines for Neglected Populations: Could a Treaty Address a Broken Pharmaceutical R&D System?
inferredcites →https://doi.org/10.5860/choice.51-3359openalex-snapshot
The entrepreneurial state: debunking public vs. private sector myths
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4650638openalex-extracted
New Compound Real Option Pricing Method with Lévy Processes for the Quality-by-Design Pharmaceutical R&D
inferred← citeshttps://doi.org/10.1007/s10198-021-01341-wopenalex-snapshot
Public health policies for the common interest: rethinking EU states’ incentives strategies when a pandemic reshuffles all interests
inferred← citeshttps://doi.org/10.1007/s10272-020-0878-0openalex-snapshot
The Coming Coronavirus Crisis: What Can We Learn?
inferred← citeshttps://doi.org/10.1016/j.cpa.2020.102247openalex-snapshot
Public value and pricing in English hospitals: Value creation or value extraction?
inferred← citeshttps://doi.org/10.1016/j.ijindorg.2022.102850openalex-snapshot
Incentives for pharmaceutical innovation: What’s working, what’s lacking
inferred← citeshttps://doi.org/10.1016/j.jebo.2023.05.039openalex-snapshot
Do patents really foster innovation in the pharmaceutical sector? Results from an evolutionary, agent-based model
inferred← citeshttps://doi.org/10.1016/s1470-2045(23)00095-5openalex-snapshot
REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment
inferred← citeshttps://doi.org/10.1017/jme.2021.8openalex-snapshot
A Market Shaping Approach for the Biopharmaceutical Industry: Governing Innovation Towards the Public Interest
inferred← citeshttps://doi.org/10.1021/acs.oprd.4c00219openalex-snapshot
Reshoring Fine Chemical and Pharmaceutical Productions
inferred← citeshttps://doi.org/10.1057/s41292-024-00341-2openalex-snapshot
The social shaping of biotechnological innovation. The case of Covid-19 protein vaccine in Cuba and the US
inferred← citeshttps://doi.org/10.1101/2025.09.10.25335461openalex-snapshot
Drug company payments to Australian healthcare professionals
inferred← citeshttps://doi.org/10.1111/apce.12341openalex-snapshot
Biomed Europa: After the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly
inferred← citeshttps://doi.org/10.1136/bmj.m1314openalex-snapshot
Cooperation as an alternative to nationalisation of the pharmaceutical industry
inferred← citeshttps://doi.org/10.1186/s12992-024-01019-xopenalex-snapshot
Pull me – push you? The disparate financing mechanisms of drug research in global health
inferred← citeshttps://doi.org/10.1371/journal.pgph.0003173openalex-snapshot
‘Our project, your problem?’ A case study of the WHO’s mRNA technology transfer programme in South Africa
inferred← citeshttps://doi.org/10.1371/journal.pone.0239610openalex-snapshot
Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
inferred← citeshttps://doi.org/10.15366/relacionesinternacionales2023.52.008openalex-snapshot
Sobre la obligatoriedad de las vacunas en tiempos de covid-19: aproximación contextual y análisis desde el Derecho y las políticas comparadas
inferred← citeshttps://doi.org/10.1590/s1679-49742021000200001openalex-snapshot
Resposta da ciência para a pandemia de COVID-19: compromisso com a vida
inferred← citeshttps://doi.org/10.21201/2024.000007openalex-snapshot
Inequality Inc. How corporate power divides our world and the need for a new era of public action
inferred← citeshttps://doi.org/10.21201/2024.000023openalex-snapshot
Unaccountable Adaptation: The Asian Development Bank’s overstated claims on climate adaptation finance
inferred← citeshttps://doi.org/10.2139/ssrn.5010538openalex-snapshot
A Public Vaccine Development Service: Public Service Logic in the Development of the Oxford Astrazeneca Covid-19 Vaccine
inferred← citeshttps://doi.org/10.22267/rus.222401.250openalex-snapshot
Soberanía sanitaria: una política prioritaria para las democracias
inferred← citeshttps://doi.org/10.34172/ijhpm.2020.166openalex-snapshot
Public Risk-Taking and Rewards During the COVID-19 Pandemic - A Case Study of Remdesivir in the Context of Global Health Equity
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.